YZYongliang Zhu

Yongliang Zhu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Yongliang Zhu has a total of 36 co-authors. Here are the top co-authors by number of shared publications:

  • Rui Wang

    Department of Gastroenterology, Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang, People’s Republic of China

    6 shared publications
  • Bin Yang

    Department of Gastroenterology, Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang, People’s Republic of China

    4 shared publications
  • Sheng Yao

    Department of Hepatobiliary and Pancreatic Surgery, Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang, People’s Republic of China

    4 shared publications
  • Tianhui Pan

    Department of Gastroenterology, Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang, People’s Republic of China

    4 shared publications
  • Jingni Wu

    Department of International Healthcare Center and General Medicine, Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang, China

    3 shared publications
  • Shuyu Li

    Department of Gastroenterology, Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang, People’s Republic of China

    3 shared publications

Latest Publications

  • Open Access

    ANKRD22 Downregulation Reprograms Lipid Metabolism to Activate the Notch/Hes1 Pathway, Driving Immunosuppressive Macrophage Polarization in Colorectal Cancer

    by Bin Yang, Liang Hong, Shuyu Li, Ruoxi Li, Rui Wang, Sheng Yao, Tianhui Pan, Dandan Zhong, Caihua Wang, Yongliang Zhu

    Background: Macrophages in colorectal cancer (CRC) are predominantly derived from monocytes, yet the mechanisms by which the tumor microenvironment (TME) regulates their differentiation dynamics and phenotypic commitment remains poorly defined. Although we previously identified ANKRD22 as a macrophage immunomodulator, the regulation of ANKRD22 by the TME and its temporal impact on monocyte‒macrophage differentiation are still unclear. Methods: We used untargeted metabolomics and cytokine microarrays to identify metabolites and cytokines from CRC cell supernatants that suppress ANKRD22 expression in macrophages. Immune infiltration in tumors was evaluated using cytometry by time-of-flight. The effects of ANKRD22 downregulation on monocyte-to-macrophage differentiation were investigated using scRNA-seq, scATAC-seq, and multiplex immunofluorescence staining. Results: CRC cell-derived metabolites and cytokines downregulated ANKRD22 expression in macrophages via the p38 MAPK/MAX pathway. Ankrd22-deficient macrophages accelerated subcutaneous tumor growth in mice, promoting the expansion of immunosuppressive CD206⁺CD163⁺ macrophage subsets and decreasing the number of CD8⁺CD44⁺CD62L− effector T cells. ANKRD22 downregulation delayed macrophage differentiation and maturation while increasing monocyte recruitment. Mechanistically, ANKRD22 suppression reduced the level of intracellular fatty acids, which in turn activated the Notch4/HES1 pathway, leading to differentiation arrest and immunosuppressive polarization. This process involved a newly identified early-differentiation immunosuppressive CD9⁺CD127⁺ macrophage subset within the TME. The combined pharmacological inhibition of Notch and long-acting IL-7 expression reversed these phenotypes, attenuated tumor growth, and diminished the CD9⁺CD127⁺ population. Conclusion: ANKRD22 downregulation reprograms fatty acid metabolism to activate the Notch4/HES1 pathway, promoting immunosuppressive macrophage polarization. ANKRD22 is a key regulator of macrophage plasticity and a promising therapeutic target for reprogramming the immunosuppressive TME in CRC.

  • Open Access

    An epitope-directed mRNA vaccine inhibits tumor metastasis through the blockade of MICA/B α1/2 shedding

    by Rui Wang, Jingni Wu, Yifeng Lin, Yufei Xiao, Bin Yang, Sheng Yao, Tianhui Pan, Zhixuan Fu, Shuyu Li, Caihua Wang, et al.


  • Open Access

    ANKRD22 participates in the proinflammatory activities of macrophages in the colon cancer tumor microenvironment

    by Xiaoying Wang, Keqing Yang, Bin Yang, Rui Wang, Yongliang Zhu, Tianhui Pan

    Tumor-associated macrophages (TAMs) are among the most common types of immune cells in the colon cancer microenvironment. Reprogramming M2-type TAMs with immunosuppressive functions into M1-type TAMs with proinflammatory functions is a novel strategy for reshaping the tumor microenvironment (TME) and enhancing the efficacy of immunotherapy in colon cancer. However, the key molecules and mechanisms underlying TAM polarization require further clarification. Our previous study suggested that ANKRD22 may play a role in regulating the functional state transition of macrophages. However, the expression levels of ANKRD22 in colon TAMs and its specific effects on tumor proliferation remain unclear. In the present study, we observed elevated ANKRD22 expression in M1-type TAMs. The expression level of ANKRD22 was positively correlated with the survival period of patients with colon cancer and with the infiltration abundance of M1-type TAMs, and ANKRD22 expression was negatively correlated with the infiltration abundance of M2-type TAMs. A significant decrease in ANKRD22 expression in macrophages cocultured with colon cancer cell culture supernatant as well as in macrophages directly derived from colorectal cancer tissues was observed. Single-cell RNA sequencing, spatial transcriptomic studies, and subcutaneous xenograft experiments in mice revealed that Ankrd22 silencing altered the subtype distribution of macrophages, attenuated their proinflammatory activity, and enhanced their protumor activity. Additionally, we identified a small-molecule ANKRD22 upregulator that could aid in the development of novel therapeutics targeting TAM remodeling.


  • Open Access

    ANKRD22 is a potential novel target for reversing the immunosuppressive effects of PMN-MDSCs in ovarian cancer

    by Huanhuan Chen, Keqing Yang, Lingxiao Pang, Jing Fei, Yongliang Zhu, Jianwei Zhou

    Background: Ovarian cancer is the deadliest type of malignant gynecological tumor. Polymorphonuclear myeloid-derived suppressor cells (PMN-MDSCs) are involved ovarian cancer and are closely related to adverse outcomes. However, the immunosuppressive mechanism of PMN-MDSCs remains elusive. Methods: The types and numbers of ANKRD22-expressing cells were investigated by bioinformatics analysis and immunohistochemical staining. Ankrd22-/- C57BL/6 mice were constructed with CRISPR-Cas9 technology. Mouse PMN-MDSCs were obtained from bone marrow (BM)-derived CD11b+Ly6G+Ly6Clow cells sorted by fluorescence-activated cell sorting with treatment of GM-CSF and IL-6, and the immunosuppressive activity of PMN-MDSCs was evaluated by flow cytometry (FCM) and ELISA. The expression level of CCR2 and the exogenous glucose uptake capacity were determined by FCM. RT-qPCR was used to detect ANKRD22 expression in CD11b+HLA-DR-CD14-CD15+ cells from human ovarian cancer tissues, and the correlations of ANKRD22 expression with the clinical characteristics and prognosis of patients were evaluated by the χ2 test. Results: We identified a novel protein involved in regulating the immunosuppressive ability of PMN-MDSCs, ANKRD22. Ankrd22 expression was high in mouse CD11b+Ly6G+Ly6Clow cells and could be significantly downregulated after exposure to a simulated microenvironmental stimulus. Knockout of Ankrd22 increased the expression level of CCR2 of CD11b+Ly6G+Ly6Clow cells and the immunosuppressive activity of PMN-MDSCs. BM-derived CD11b+Ly6G+Ly6Clow cells of Ankrd22-/- mice significantly promoted the proliferation of ovarian cancer cells in tumor xenograft mouse models. Mechanistically, RNA sequencing showed that Wdfy1 expression was obviously increased in Ankrd22-knockout BM-derived CD11b+Ly6G+ Ly6Clow cells and that ectopic expression of Wdfy1 increased the levels of Arg1, Inos, Ido and Pdl1 in Ankrd22+/+ PMN-MDSCs derived from BM-derived CD11b+Ly6G+Ly6Clow cells. Surprisingly, an ANKRD22-activating candidate small-molecule compound attenuated the immunosuppressive activity of Ankrd22+/+ PMN-MDSCs. Finally, we found that low ANKRD22 levels in CD11b+HLA-DR-CD14-CD15+ cells derived from primary ovarian tissues were associated with a more advanced International Federation of Gynecology and Obstetrics stage, a higher recurrence rate, and a higher neutrophil-to-lymphocyte ratio. Conclusions: These results suggest that ANKRD22 is a potential novel target for reversing the immunosuppressive effects of PMN-MDSCs.


  • Open Access

    ANKRD22 is a novel therapeutic target for gastric mucosal injury

    by Rui Wang, Youhe Wu, Yue Zhu, Sheng Yao, Yongliang Zhu


  • Open Access

    Circulating MiR-1290 as a potential diagnostic and disease monitoring biomarker of human gastrointestinal tumors

    by Liyi Xu, Yangke Cai, Xiao Chen, Yongliang Zhu, Jianting Cai

    Background: Gastrointestinal tumors are a leading cause of mortality worldwide. As shown in our previous study, miR-1290 is overexpressed in colorectal cancer (CRC) and promotes tumor progression. We therefore aimed to explore the potential of circulating miR-1290 as a biomarker for gastrointestinal cancer. Methods: A serum miRNA sequencing analysis was performed. Then, circulating miRNA detection technologies were established. The expression of miR-1290 was analyzed in gastrointestinal tumor cell lines and culture supernatants. Expression levels of circulating miR-1290 in clinical samples were examined. Associations between miR-1290 expression and clinicopathologic characteristics were analyzed. Xenograft models were generated to assess the fluctuation in serum miR-1290 levels during disease progression. Results: Through miRNA sequencing, we identified that miR-1290 was overexpressed in serum samples from patients with CRC. We confirmed that human gastrointestinal tumor cells express and secrete miR-1290. The circulating miR-1290 levels was up-regulated in patients with pancreatic cancer (PC) (p < 0.01), CRC (p < 0.05), and gastric cancer (GC) (p < 0.01). High miR-1290 expression levels were associated with tumor size, lymphatic invasion, vascular invasion, distant metastasis, tumor differentiation and AJCC stage in patients with PC and CRC. The area under the curve (AUC) was 0.8857 in patients with PC, with 60.9% sensitivity and 90.0% specificity. The AUC was 0.7852 in patients with CRC, with 42.0% sensitivity and 90.0% specificity. In patients with GC, the AUC was 0.6576, with 26.0% sensitivity and 90.0% specificity. The in vivo model verified that the circulating miR-1290 level was significantly increased after tumor formation and decreased after drug treatment. Conclusions: Our findings indicate that circulating miR-1290 is a potential biomarker for gastrointestinal cancer diagnosis and monitoring.


  • Open Access

    ANKRD22 Drives Rapid Proliferation of Lgr5+ Cells and Acts as a Promising Therapeutic Target in Gastric Mucosal Injury

    by Jingwen Liu, Jingni Wu, Rui Wang, Dandan Zhong, Yiqing Qiu, Hongping Wang, Zhenya Song, Yongliang Zhu


  • Open Access

    ANKRD22, a novel tumor microenvironment-induced mitochondrial protein promotes metabolic reprogramming of colorectal cancer cells

    by Tianhui Pan, Jingwen Liu, Song Xu, Qiao Yu, Hongping Wang, Hongxiang Sun, Jia Wu, Yue Zhu, Jianwei Zhou, Yongliang Zhu

    Background: The leading cause of poor prognosis in colorectal cancer (CRC) is the presence of colorectal cancer-initiating cells (CCICs). The interplay between the tumor microenvironment (TME) and CRC cells induces reacquisition of initiating cell characteristics, but the underlying mechanisms remain elusive.